试验雷达 AI | ||
|---|---|---|
临床试验 NCT06136624 (OMAHA-003) 针对转移性前列腺癌目前招募中。请查看临床试验雷达卡片视图和 AI 发现工具了解所有详情，或在此提出任何问题。 | ||
一个试验符合过滤标准
卡片视图
返回搜索
默沙东Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) (OMAHA-003) III期 1,310 随机化 开放性试验 总生存期
临床试验详情主要以英语提供。然而，试验雷达 AI可以提供帮助！只需点击“试验详解”即可查看和讨论您选择的语言的试验信息。
临床试验NCT06136624 (OMAHA-003)旨在研究治疗，主要针对转移性前列腺癌。这是一项III期 干预性研究试验，目前试验状态为招募中。试验始于2023年12月31日，计划招募1,310名患者。该研究由默沙东主导，预计于2028年8月2日完成。试验数据来源于ClinicalTrials.gov，最后更新时间为2026年3月20日。
简要概括
This is a phase 3, randomized, open-label study of opevesostat compared to alternative abiraterone acetate or enzalutamide in participants with metastatic castration-resistant prostate cancer (mCRPC) with respect to overall survival (OS) in participants with mCRPC previously treated with next-generation hormonal agent (NHA) and taxane-based chemotherapy. It is hypothesized that opevesostat is superior with respect to...显示更多
官方标题
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy (OMAHA-003)
疾病
转移性前列腺癌出版物
关于此临床试验发表的科学文章和研究论文：其他研究标识符
- OMAHA-003
- 5684-003
- 2023-504899-25-00 (其他标识符) (EU CT)
- MK-5684-003 (其他标识符) (MSD)
- jRCT2031240029 (注册标识符) (Japan Registry of Clinical Trials (jRCT))
- U1111-1287-5304 (注册标识符) (UTN)
NCT编号
实际开始日期
2023-12-31
最近更新发布
2026-03-20
预计完成日期
2028-08-02
计划入组人数
1,310
研究类型
干预性研究
试验分期 (阶段)
III期
试验状态
招募中
主要目的
治疗方法
分配方式
随机
干预模型
平行
盲法
无（开放性试验）
试验组/干预措施
| 参与者组/试验组 | 干预措施/治疗方法 |
|---|---|
实验性Opevesostat Participants receive opevesostat 5 mg by oral tablets twice daily (bid) plus dexamethasone 1.5 mg by oral tablets once daily (qd) and 0.1 mg fludrocortisone acetate by oral tablet qd until progression. Hydrocortisone 100 mg (oral or intramuscular \[IM\]) dose will also be provided to participants for use as rescue medication. | Opevesostat Administered orally Hydrocortisone Administered orally or IM as a rescue medication Fludrocortisone acetate Administered orally Dexamethasone Administered orally as rescue medication |
阳性对照Abiraterone Acetate or Enzalutamide Participants receive abiraterone 1000 mg qd by oral tablets plus prednisone 5 mg bid by oral tablets or enzalutamide 160 mg qd by oral tablets. | 醋酸阿比特龙 Administered orally Enzalutamide Administered orally Prednisone Administered orally |
主要终点
次要终点
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Overall Survival (OS) in Androgen Receptor Ligand Binding Domain (AR LBD) Mutation-Positive Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~54 months |
OS in AR LBD Mutation-Negative Participants | OS is defined as time from randomization to death due to any cause. OS in AR LBD mutation-negative participants will be reported for each study arm. | Up to ~54 months |
| 结果指标 | 度量标准描述 | 时间框架 |
|---|---|---|
Radiographic Progression-free Survival (rPFS) Per Prostate Cancer Working Group-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review in AR LBD Mutation-Positive Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
rPFS Per Prostate Cancer Working Group-modifiedRECIST 1.1 as Assessed by Blinded Independent Central Review in AR LBD Mutation-Negative Participants | rPFS is defined as the time from randomization to the first documented disease progression per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by Blinded Independent Central Review (BICR) or death due to any cause, whichever occurs first. rPFS in AR LBD mutation-positive participants will be reported for each study arm. | Up to ~36 months |
Time to Initiation of the First Subsequent Anti-Cancer Therapy or Death (TFST) | TFST is defined as the time from randomization to initiation of the first subsequent anticancer therapy or death, whichever occurs first. | Up to ~54 months |
Objective Response (OR) | OR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Duration of Response (DOR) | DOR is determined by PCWG-modified RECIST 1.1 as assessed by BICR. | Up to ~54 months |
Time to Pain Progression (TTPP) | TTPP is assessed by Brief Pain Inventory-Short Form (BPI-SF) Item 3 ("Worst Pain in 24 Hours") and opiate analgesic use (Analgesic Quantification Algorithm \[AQA\] Score). | Up to ~54 months |
Time to Prostate-specific Antigen (PSA) Progression | The time from randomization to PSA progression. The PSA progression date is defined as the date of either: 1) ≥25% increase and ≥2 ng/mL above the nadir, confirmed by a second value ≥3 weeks later if there is PSA decline from baseline 2) ≥25% increase and ≥2 ng/mL increase from baseline beyond 12 weeks if there is no PSA decline from baseline. | Up to ~54 months |
Time to First Symptomatic Skeletal-related Event (SSRE) | The time from randomization to the first occurrence of any of the following symptomatic skeletal-related events: 1) Use of EBRT to prevent or relieve skeletal symptoms; 2) new symptomatic pathologic bone fracture (vertebral or nonvertebral); 3) spinal cord compression; or 4) tumor-related orthopedic surgical intervention. | Up to ~54 months |
Number of Participants Who Experience an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
Number of Participants Who Discontinue Study Treatment Due to an Adverse Event | An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. | Up to ~54 months |
参与助手
资格标准
适龄参与研究
儿童, 成人, 老年人
适龄性别
全部
- Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology.
- Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months before Screening
- Has current evidence of distant metastatic disease (M1 disease) documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI).
- Has disease that progressed during or after treatment with 1 novel hormonal agent (NHA)
- Has received 1 but no more than 2 taxane-based chemotherapy regimens for metastatic castration-resistant prostate cancer (mCRPC) and has had progressive disease (PD) during or after treatment
- Has ongoing androgen deprivation with serum testosterone <50 ng/dL (<1.7 nM)
- Has provided tumor tissue from a fresh core or excisional biopsy from soft tissue not previously irradiated
- Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization
- Has had prior treatment with PARPi or were deemed ineligible to receive treatment by the investigator or have refused PARPi treatment
- Has received prior 177Lu-PSMA-617 or were deemed ineligible to receive 177Lu-PSMA-617 treatment by the investigator or refused 177Lu-PSMA-617 treatment
- Participants who have not received cabazitaxel can be enrolled if they are ineligible for cabazitaxel treatment as determined by the investigator or have refused treatment
- If participant received first generation anti-androgen therapy before screening, the participant has evidence of disease progression >4 weeks since the last flutamide treatment and >6 weeks since the last bicalutamide or nilutamide treatment
- Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses for ≥ 4 weeks before the date of randomization
- Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on antiretroviral therapy (ART)
- Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load before randomization
- Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at Screening.
- Participants who can produce sperm must agree to the following during the study treatment period and for at least 7 days after the last dose of opevesostat, for at least 30 days after the last dose of abiraterone acetate, and for at least 3 months after the last dose of enzalutamide: EITHER be abstinent OR must agree to use male condom
- Has a gastrointestinal disorder that might affect absorption
- Has a history of pituitary dysfunction
- Has poorly controlled diabetes mellitus
- Has clinically significant abnormal serum potassium or sodium level
- Has a history of active or unstable cardio/cerebro-vascular disease, including thromboembolic events
- Has a history of seizure within 6 months of providing documented informed consent or any condition that may predispose to seizures within 12 months before the date of randomization
- Has a history of clinically significant ventricular arrhythmias
- Has received an anticancer monoclonal antibody (mAb) within 4 weeks before the date of randomization, or has not recovered from adverse events (AEs) due to mAbs administered more than 4 weeks before the date of randomization
- Has undergone major surgery, including local prostate intervention (except prostate biopsy), within 28 days before the date of randomization, and has not recovered from the toxicities and/or complications
- Participants who have not adequately recovered from major surgery or have ongoing surgical complications
- Has used herbal or medicinal products that may have hormonal anti-prostate cancer activity and/or are known to decrease prostate-specific Antigen (PSA) (eg, saw palmetto, megesterol acetate, citrus pectin polysaccharide) within 4 weeks before the date of randomization
- Has received radium-223 or lutetium-177 within 4 weeks before the date of randomization, or has not recovered to Grade ≤1 or baseline from AEs due to radium-223 or lutetium-177 administered more than 4 weeks before the date of randomization
- Has received treatment with 5-αreductase inhibitors (eg, finasteride or dutasteride), estrogens, or cyproterone within 4 weeks before the date of randomization
- Has received colony-stimulating factors within 28 days before the date of randomization
- Has received a whole blood transfusion in the last 120 days before the date of randomization. Packed red blood cells and platelet transfusions are acceptable if not given within 28 days of the date of randomization
- Has received prior targeted small molecule therapy or NHA treatment within 4 weeks before the first dose of study intervention as follows: enzalutamide or apalutamide within 3 weeks or abiraterone acetate + prednisone or darolutamide within 2 weeks
- Has a "superscan" bone scan
- Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication
- Has a known additional malignancy that is progressing or has required active treatment within the past 3 years
- Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis
- Has an active autoimmune disease that has required systemic treatment in past 2 years
- Has an active infection requiring systemic therapy
- Has concurrent active HBV or known active HCV infection
- Has a history of long QTc syndrome
- Has any of the following at Screening Visit: hypotension (systolic BP <110 mm Hg) or uncontrolled hypertension (systolic BP ≥160 mm Hg or diastolic BP ≥90 mm Hg, in 2 out of 3 recordings with optimized antihypertensive therapy)
- Is unable to swallow capsules/tablets
- Is currently being treated with cytochrome 450-inducing antiepileptic drugs for seizures
- Participants on an unstable dose of thyroid hormone therapy within 6 months before the start of the study intervention
- Received prior systemic anticancer therapy including investigational agents within 4 weeks before the first dose of study intervention
- Received prior radiotherapy within 2 weeks of start of study intervention, or radiation-related toxicities, requiring corticosteroids
- Received a live or live-attenuated vaccine within 30 days before the first dose of study intervention
- Systemic use of the following medications within 2 weeks before the first dose of study intervention: strong CYP3A4 inducers (eg, avasimibe, carbamazepine, lumacaftor, phenobarbital, rifampicin, rifapentine, or St John's Wort); P-gp inhibitors (eg, erythromycin, clarithromycin, rifampicin, ketoconazole, itraconazole, posaconazole, artesunate-pyronaridine, ritonavir, indinavir, nelfinavir, atazanavir, glecaprevir-pibrentasvir, simeprevir, ledipasvir-sofosbuvir, verapamil, diltiazem, dronedarone, propafenone, quinidine, cyclosporine, valspodar, or milk thistle \[Silybum marianum\])
- Use of aldosterone antagonist (eg, spironolactone, eplerenone) and phenytoin within 4 weeks before the start of the study intervention
Orion Corporation9 个活跃的临床试验可供探索研究中心联系人
联系人: Toll Free Number, 1-888-577-8839, [email protected]
281 位于 36 个国家/地区的研究中心
Anhui
Second Affiliated hospital of Anhui Medical University-Urology ( Site 0408), Hefei, Anhui, 230000, China
Study Coordinator, 联系人, +86 02782201756
招募中
Beijing Municipality
Peking University First Hospital-Urology ( Site 0390), Beijing, Beijing Municipality, 100034, China
Study Coordinator, 联系人, +86 (010) 64008229
招募中
Beijing Friendship Hospital Affiliate of Capital University ( Site 0396), Beijing, Beijing Municipality, 100050, China
Study Coordinator, 联系人, +86(010)63138375
招募中
Beijing Cancer hospital-Urinary Surgery ( Site 0395), Beijing, Beijing Municipality, 100142, China
Study Coordinator, 联系人, 86 010 8812 1122
招募中
Chongqing Municipality
The First Affiliated Hospital of Chongqing Medical University ( Site 0427), Chongqing, Chongqing Municipality, 400010, China
Study Coordinator, 联系人, 023 89012012
招募中
Chongqing University Cancer Hospital ( Site 0416), Chongqing, Chongqing Municipality, 400030, China
Study Coordinator, 联系人, 02365075629
招募中
Southwest Hospital of Third Military Medical University ( Site 0420), Chongqing, Chongqing Municipality, 400038, China
Study Coordinator, 联系人, 023 68765878
招募中
Chongqing Three Gorges Central Hospital's ( Site 0426), Chongqing, Chongqing Municipality, 404100, China
Study Coordinator, 联系人, 023 58103150
招募中
Fujian
The First Affiliated Hospital Of Fujian Medical University-Urology ( Site 0414), Fuzhou, Fujian, 350005, China
Study Coordinator, 联系人, +86059187983333
招募中
The First Affiliated hospital of Xiamen University-Urology ( Site 0415), Xiamen, Fujian, 361003, China
Study Coordinator, 联系人, 0592-2132222
招募中
Guangdong
The First Affiliated Hospital of Guangzhou Medical University ( Site 0412), Guangzhou, Guangdong, 510120, China
Study Coordinator, 联系人, (020) 83062114
招募中
Sun Yat-sen University Cancer Center-Internal medicine ( Site 0413), Guangzhou, Guangdong, 511400, China
Study Coordinator, 联系人, +8602087343533
招募中
Hubei
Tongji Hospital Tongji Medical,Science & Technology ( Site 0407), Wuhan, Hubei, 430000, China
Study Coordinator, 联系人, 027-83665555
招募中
Hubei Cancer Hospital-Urinary surgery ( Site 0406), Wuhan, Hubei, 430079, China
Study Coordinator, 联系人, 8613907110640
招募中
Hunan
Hunan Cancer Hospital ( Site 0405), Changsha, Hunan, 410013, China
Study Coordinator, 联系人, 073189762270
招募中
Jiangsu
First Huai'an Hospital Affiliated to Nanjing Medical University ( Site 0436), Huaian, Jiangsu, 223300, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School-Urology ( Site 0377), Nanjing, Jiangsu, 210008, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Affiliated hospital of Jiangnan university ( Site 0434), Wuxi, Jiangsu, 214122, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Jiangxi
Jiangxi Cancer Hospital ( Site 0386), Nanchang, Jiangxi, 330029, China
Study Coordinator, 联系人, 86079188317256
招募中
Shaanxi
The Second Affiliated Hospital of Xi'an Jiaotong University ( Site 0394), Xi'an, Shaanxi, 710004, China
Study Coordinator, 联系人, 029-87679000
招募中
The First Affiliated Hospital of Xi'an Jiaotong University-Oncology ( Site 0393), Xi'an, Shaanxi, 710061, China
Study Coordinator, 联系人, 029-85323112
招募中
Shandong
Yantai Yuhuangding Hospital ( Site 0397), Yantai, Shandong, 264099, China
Study Coordinator, 联系人, 86 0535 6691999
招募中
Shangai
Zhongshan Hospital of Fudan University (0430), Shanghai, Shangai, 200032, China
Jianming Guo, 联系人, 13681971306, [email protected]
招募中
Shanghai Municipality
Fudan University Shanghai Cancer Center-Urology department ( Site 0376), Shanghai, Shanghai Municipality, 200000, China
Study Coordinator, 联系人, 021-38196379
招募中
Huadong Hospital Affiliated to Fudan University-Urology ( Site 0388), Shanghai, Shanghai Municipality, 200041, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Sichuan
The Third People's Hospital of Chengdu (CDTPH) ( Site 0428), Chengdu, Sichuan, 500643, China
Study Coordinator, 联系人, 67566947
招募中
West China Hospital, Sichuan University-Urology Surgery ( Site 0417), Chengdu, Sichuan, 610041, China
Study Coordinator, 联系人, +86028-85422114
招募中
Nanchong Central Hospital-urology ( Site 0422), Nanchong, Sichuan, 500643, China
Study Coordinator, 联系人, 08172606822
招募中
Suining Central Hospital ( Site 0437), Suining, Sichuan, 629000, China
Study Coordinator, 联系人, 08252292093
招募中
Tianjin Municipality
Tianjin Medical University Cancer Institute & Hospital ( Site 0392), Tianjin, Tianjin Municipality, 300060, China
Study Coordinator, 联系人, +862223340123
招募中
The Second Hospital of Tianjin Medical University ( Site 0391), Tianjin, Tianjin Municipality, 300211, China
Study Coordinator, 联系人, +8602288326748
招募中
Xinjiang
Xinjiang Medical University Cancer Hospital - Urumqi-Urology ( Site 0419), Ürümqi, Xinjiang, 830000, China
Study Coordinator, 联系人, 86 09917819156
招募中
Yunnan
The Second Affiliated Hospital Of Kunming Medical University ( Site 0429), Kunming, Yunnan, 650033, China
Study Coordinator, 联系人, 087165351281
招募中
Yunnan Province Cancer Hospital ( Site 0418), Kunming, Yunnan, 650107, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Zhejiang
Zhejiang Provincial People's Hospital-Urology ( Site 0378), Hangzhou, Zhejiang, 310014, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
Zhejiang Cancer Hospital ( Site 0435), Hangzhou, Zhejiang, 310022, China
Study Coordinator, 联系人, 0571-88122261
招募中
The First Hospital of Jiaxing-urology ( Site 0380), Jiaxing, Zhejiang, 314001, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
The First Affiliated Hospital of Ningbo University ( Site 0383), Ningbo, Zhejiang, 315010, China
Study Coordinator, 联系人, 86057487085588
招募中
The First Affiliated Hospital of Wenzhou Medical University-Urology Surgery ( Site 0379), Wenzhou, Zhejiang, 325000, China
Study Coordinator, 联系人, 1-888-577-8839
招募中
China Medical University Hospital-Department of Urology ( Site 1503), Taichung, 40447, Taiwan
Study Coordinator, 联系人, +886-4-2205-2121
招募中
National Cheng Kung University Hospital-Urology ( Site 1502), Tainan, 704, Taiwan
Study Coordinator, 联系人, +886-6-2353535
招募中
National Taiwan University Hospital-Urology ( Site 1506), Taipei, 10002, Taiwan
进行中（不再招募）
Taipei Veterans General Hospital ( Site 1505), Taipei, 112, Taiwan
Study Coordinator, 联系人, +886-2-28712121
招募中
Chang Gung Medical Foundation-Linkou Branch-Medical Oncology ( Site 1504), Taoyuan District, 333, Taiwan
Study Coordinator, 联系人, +886-3-3281200
招募中
Central Singapore
National University Hospital ( Site 1376), Singapore, Central Singapore, 119074, Singapore
Study Coordinator, 联系人, 1-888-577-8839
招募中
National Cancer Centre Singapore ( Site 1377), Singapore, Central Singapore, 168583, Singapore
Study Coordinator, 联系人, +65-64368000
招募中
Tan Tock Seng Hospital-Medical Oncology ( Site 1378), Singapore, Central Singapore, 308433, Singapore
Study Coordinator, 联系人, +65-62566011
招募中
Johor
Hospital Sultan Ismail ( Site 1081), Johor Bahru, Johor, 81100, Malaysia
Study Coordinator, 联系人, +6073565155
招募中
Kuala Lumpur
University Malaya Medical Centre ( Site 1077), Lembah Pantai, Kuala Lumpur, 59100, Malaysia
进行中（不再招募）
Putrajaya
National Cancer Institute ( Site 1079), Putrajaya, Putrajaya, 62250, Malaysia
Study Coordinator, 联系人, +60388925418
招募中
Sarawak
Sarawak General Hospital-Radiotherapy Unit ( Site 1076), Kuching, Sarawak, 93586, Malaysia
Study Coordinator, 联系人, +6082276820
招募中
Hospital Kuala Lumpur-Radiotherapy and Oncology ( Site 1078), Kuala Lumpur, 50586, Malaysia
Study Coordinator, 联系人, +60326155810
招募中
Queen Mary Hospital ( Site 0727), Hong Kong, Hong Kong
Study Coordinator, 联系人, +85222553838
招募中
Prince of Wales Hospital ( Site 0730), Shatin, Hong Kong
Study Coordinator, 联系人, +85235052211
招募中
California
University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange, California, 92868, United States
进行中（不再招募）
Stanford Cancer Center ( Site 0036), Palo Alto, California, 94304, United States
Study Coordinator, 联系人, 650-725-2078
招募中
Kaiser Permanente Riverside Medical Center ( Site 0099), Riverside, California, 92505, United States
Study Coordinator, 联系人, 951-809-8361
招募中
Colorado
Anschutz Cancer Pavilion ( Site 0046), Aurora, Colorado, 80045, United States
Study Coordinator, 联系人, 302-290-3598
招募中
University of Colorado Health - Highlands Ranch Hospital ( Site 0111), Highlands Ranch, Colorado, 80129, United States
Study Coordinator, 联系人, 302-290-3598
招募中
Colorado Clinical Research ( Site 0067), Lakewood, Colorado, 80228, United States
进行中（不再招募）
University of Colorado Health - Lone Tree Medical Center ( Site 0112), Lone Tree, Colorado, 80124, United States
Study Coordinator, 联系人, 720-848-5146
招募中
Connecticut
Yale-New Haven Hospital-Yale Cancer Center ( Site 0064), New Haven, Connecticut, 06510, United States
Study Coordinator, 联系人, 203-737-8076
招募中
Florida
Florida Cancer Specialists - South ( Site 7003), Fort Myers, Florida, 33901, United States
Study Coordinator, 联系人, 727-364-9201
招募中
Bruce W. Carter Veterans Affairs Medical Center ( Site 0082), Miami, Florida, 33125, United States
进行中（不再招募）
University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 0051), Miami, Florida, 33136, United States
Study Coordinator, 联系人, 305-243-1543
招募中
Illinois
University of Illinois at Chicago ( Site 0105), Chicago, Illinois, 60612, United States
Study Coordinator, 联系人, 973-330-2391
招募中
University of Chicago Medical Center ( Site 0045), Chicago, Illinois, 60637, United States
Study Coordinator, 联系人, 773-702-7609
招募中
Iowa
University of Iowa ( Site 0047), Iowa City, Iowa, 52242, United States
Study Coordinator, 联系人, 319-353-8155
招募中
Kentucky
University of Kentucky Chandler Medical Center ( Site 0048), Lexington, Kentucky, 40536, United States
进行中（不再招募）
Louisiana
Ochsner Clinic Foundation ( Site 0108), New Orleans, Louisiana, 70121, United States
进行中（不再招募）
Maryland
Baltimore Veterans Affairs Medical Center ( Site 0069), Baltimore, Maryland, 21201, United States
Study Coordinator, 联系人, 410-707-4011
招募中
Greenebaum Comprehensive Cancer Center ( Site 0049), Baltimore, Maryland, 21201, United States
Study Coordinator, 联系人, 410-707-4011
招募中
Michigan
Henry Ford Hospital ( Site 0015), Detroit, Michigan, 48202, United States
进行中（不再招募）
Minnesota
M Health Fairview Clinics and Surgery Center ( Site 0019), Minneapolis, Minnesota, 55455, United States
Study Coordinator, 联系人, 612-626-1422
招募中
Metro-Minnesota Community Clinical Oncology ( Site 0014), Saint Louis Park, Minnesota, 55416, United States
Study Coordinator, 联系人, 952-993-3252
招募中
Missouri
Washington University School of Medicine-Internal Medicine/Oncology ( Site 0062), St Louis, Missouri, 63110, United States
进行中（不再招募）
Nebraska
University Of Nebraska Medical Center-Oncology/Hematology ( Site 0095), Omaha, Nebraska, 68105, United States
Study Coordinator, 联系人, 402-559-8500
招募中
Nevada
Comprehensive Cancer Centers of Nevada ( Site 0010), Las Vegas, Nevada, 89148, United States
Study Coordinator, 联系人, 702-952-1251
招募中
New Jersey
Atlantic Health System Morristown Medical Center ( Site 0115), Morristown, New Jersey, 07960, United States
Study Coordinator, 联系人, 973-971-7960
招募中
Rutgers Cancer Institute of New Jersey ( Site 0033), New Brunswick, New Jersey, 08901, United States
进行中（不再招募）
New York
James J. Peters VA Medical Center ( Site 0088), The Bronx, New York, 10468, United States
Study Coordinator, 联系人, 718-584-9000
招募中
Ohio
University Hospitals Cleveland Medical Center ( Site 0043), Cleveland, Ohio, 44106, United States
Study Coordinator, 联系人, 216-844-3951
招募中
Oregon
Oregon Health and Science University ( Site 0028), Portland, Oregon, 97239, United States
进行中（不再招募）
VA Portland Health Care System ( Site 0058), Portland, Oregon, 97239, United States
Study Coordinator, 联系人, 503-220-8262
招募中
Pennsylvania
AHN Allegheny General Hospital ( Site 0001), Pittsburgh, Pennsylvania, 15212, United States
进行中（不再招募）
South Carolina
Ralph H. Johnson VA Health Care System (RHJVAHCS)-Urology ( Site 0083), Charleston, South Carolina, 29401, United States
进行中（不再招募）
South Dakota
Avera Cancer Institute - Pierre ( Site 0118), Pierre, South Dakota, 57501, United States
Study Coordinator, 联系人, 605-224-3370
招募中
Avera Cancer Institute- Research ( Site 0094), Sioux Falls, South Dakota, 57105, United States
Study Coordinator, 联系人, 605-322-6900
招募中
Avera Cancer Institute - Yankton ( Site 0117), Yankton, South Dakota, 57078, United States
Study Coordinator, 联系人, 605-655-1800
招募中
Tennessee
SCRI Oncology Partners ( Site 7000), Nashville, Tennessee, 37203, United States
Study Coordinator, 联系人, 615-218-4647
招募中
Texas
Texas Oncology - Central/South Texas ( Site 8003), Austin, Texas, 78731, United States
Study Coordinator, 联系人, 512-427-9400
招募中
Texas Oncology - DFW ( Site 8001), Dallas, Texas, 75246, United States
进行中（不再招募）
Texas Oncology - Gulf Coast ( Site 8002), The Woodlands, Texas, 77380, United States
Study Coordinator, 联系人, 713-467-1722
招募中
Virginia
University of Virginia Health System ( Site 0054), Charlottesville, Virginia, 22908, United States
Study Coordinator, 联系人, 434-327-3029
招募中
VCU Health Adult Outpatient Pavillion ( Site 0061), Richmond, Virginia, 23219, United States
进行中（不再招募）
Blue Ridge Cancer Care ( Site 0004), Roanoke, Virginia, 24014, United States
Study Coordinator, 联系人, 540-982-0237
招募中
Washington
Fred Hutchinson Cancer Center ( Site 0013), Seattle, Washington, 98109, United States
Study Coordinator, 联系人, 617-413-9079
招募中
Wisconsin
MEDICAL COLLEGE OF WISCONSIN ( Site 0020), Milwaukee, Wisconsin, 53226, United States
Study Coordinator, 联系人, 414-805-4600
招募中
Buenos Aires
Hospital Británico de Buenos Aires-Oncology ( Site 0202), Ciudad Autónoma de Buenos Aires, Buenos Aires, C1280AEB, Argentina
Study Coordinator, 联系人, 1143096839
招募中
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0201), Mar del Plata, Buenos Aires, B7600FZO, Argentina
Study Coordinator, 联系人, 02234963224
招募中
Buenos Aires F.D.
Instituto Alexander Fleming-Alexander Fleming ( Site 0206), Buenos Aires, Buenos Aires F.D., 1426ANZ, Argentina
Study Coordinator, 联系人, 1-888-577-8839
招募中
Asociación de Beneficencia Hospital Sirio Libanés ( Site 0205), Buenos Aires, Buenos Aires F.D., C1419AHN, Argentina
Study Coordinator, 联系人, 1-888-577-8839
招募中
Santa Fe Province
Sanatorio Parque ( Site 0208), Rosario, Santa Fe Province, S2000DVC, Argentina
Study Coordinator, 联系人, 1-888-577-8839
招募中
Hospital Aleman-Oncology ( Site 0207), Buenos Aires, C1118AAT, Argentina
Study Coordinator, 联系人, 01148277000
招募中
Fundacion Centro Oncologico de Integración Regional-Medical Oncology ( Site 0204), Mendoza, M5500AYB, Argentina
进行中（不再招募）
New South Wales
Dubbo Hospital ( Site 0235), Dubbo, New South Wales, 2830, Australia
Study Coordinator, 联系人, 0268096200
招募中
Macquarie University-MQ Health Clinical Trials Unit ( Site 0234), Macquarie University, New South Wales, 2109, Australia
Study Coordinator, 联系人, 0298122979
招募中
Westmead Hospital ( Site 0232), Westmead, New South Wales, 2145, Australia
进行中（不再招募）
Queensland
Princess Alexandra Hospital-Cancer Care Serices ( Site 0237), Brisbane, Queensland, 4102, Australia
Study Coordinator, 联系人, +6173176 9289
招募中
Victoria
Peter MacCallum Cancer Centre-Parkville Cancer Clinical Trials Unit (PCCTU) ( Site 0230), Melbourne, Victoria, 3000, Australia
进行中（不再招募）
Styria
Medizinische Universität Graz-Innere Medizin Klin. Abt. Onkologie ( Site 0280), Graz, Styria, 8036, Austria
Study Coordinator, 联系人, 1-888-577-8839
招募中
Upper Austria
Ordensklinikum Linz GmbH Elisabethinen-Urologie ( Site 0276), Linz, Upper Austria, 4020, Austria
Study Coordinator, 联系人, +4373276774724
招募中
Klinikum Wels-Grieskirchen GmbH ( Site 0279), Wels, Upper Austria, 4600, Austria
Study Coordinator, 联系人, +4372424152328
招募中
Espírito Santo
Hospital Santa Rita de Cassia-Centro de Pesquisa Clínica ( Site 0320), Vitória, Espírito Santo, 29041-295, Brazil
进行中（不再招募）
Estado de Bahia
Obras Sociais Irma Dulce ( Site 0302), Salvador, Estado de Bahia, 40415-006, Brazil
进行中（不再招募）
Minas Gerais
Hospital Felicio Rocho ( Site 0317), Belo Horizonte, Minas Gerais, 30110-934, Brazil
进行中（不再招募）
Hospital Mario Penna ( Site 0309), Belo Horizonte, Minas Gerais, 30380-472, Brazil
进行中（不再招募）
Paraná
Hospital Universitário Evangélico Mackenzie-Centro de Oncologia Mackenzie ( Site 0314), Curitiba, Paraná, 80440-220, Brazil
进行中（不再招募）
Santa Catarina
Clínica de Neoplasias Litoral ( Site 0305), Itajaí, Santa Catarina, 88301-220, Brazil
Study Coordinator, 联系人, +5547984046243
招募中
São Paulo
Hospital Universitário São Francisco de Assis - Bragança Paulista ( Site 0308), Bragança Paulista, São Paulo, 12916-542, Brazil
进行中（不再招募）
A. C. Camargo Cancer Center ( Site 0310), São Paulo, São Paulo, 01509-010, Brazil
进行中（不再招募）
Alberta
Cross Cancer Institute ( Site 0332), Edmonton, Alberta, T6G 1Z2, Canada
Study Coordinator, 联系人, 7804328762
招募中
Ontario
The Ottawa Hospital - General Campus-The Ottawa Hospital Cancer Centre ( Site 0336), Ottawa, Ontario, K1H 8L6, Canada
Study Coordinator, 联系人, 613-737-7700
招募中
Sunnybrook Research Institute ( Site 0331), Toronto, Ontario, M4N 3M5, Canada
Study Coordinator, 联系人, 647-533-1023
招募中
Princess Margaret Cancer Centre ( Site 0330), Toronto, Ontario, M5G 2M9, Canada
Study Coordinator, 联系人, (416) 946-4501
招募中
Quebec
Centre Intégré de Santé et de Services Sociaux de la Montérégie-Centre ( Site 0328), Greenfield Park, Quebec, J4V 2H1, Canada
Study Coordinator, 联系人, 4504665000 ext 3226
招募中
Centre Hospitalier de l'Université de Montréal ( Site 0326), Montreal, Quebec, H2X 3E4, Canada
进行中（不再招募）
Centre intégré de cancérologie du CHU de Québec Université Laval, Hôpital de l'Enfant-Jésus ( Site 0327), Québec, Quebec, G1J 1Z4, Canada
Study Coordinator, 联系人, 418 525-4444
招募中
Centre intégré universitaire de santé et de services sociaux de l'Estrie - Centre Hospitalier Univer ( Site 0329), Sherbrooke, Quebec, J1H 5H4, Canada
进行中（不再招募）
Coquimbo Region
IC La Serena Research ( Site 0356), La Serena, Coquimbo Region, 1720430, Chile
进行中（不再招募）
Los Ríos Region
Clinical Research Chile SpA ( Site 0358), Valdivia, Los Ríos Region, 5110683, Chile
进行中（不再招募）
Maule Region
Clinica Universidad Catolica del Maule-Oncology ( Site 0355), Talca, Maule Region, 3465584, Chile
Study Coordinator, 联系人, 1-888-577-8839
招募中
Region M. de Santiago
FALP ( Site 0353), Santiago, Region M. de Santiago, 7500921, Chile
进行中（不再招募）
Pontificia Universidad Catolica de Chile-Hemato-Oncology ( Site 0354), Santiago, Region M. de Santiago, 8330024, Chile
Study Coordinator, 联系人, 1-888-577-8839
招募中
Bradfordhill-Clinical Area ( Site 0351), Santiago, Region M. de Santiago, 8420383, Chile
Study Coordinator, 联系人, 1-888-577-8839
招募中
Bradford Hill Norte ( Site 0357), Antofagasta, 1240000, Chile
进行中（不再招募）
Bogota D.C.
Clinica Colsanitas S.A, Sede Clínica Universitaria Colombia-Center Investigator ( Site 0501), Bogotá, Bogota D.C., 111321, Colombia
进行中（不再招募）
Cesar Department
Sociedad De Oncología y Hematología Del Cesar SAS-Oncology ( Site 0502), Valledupar, Cesar Department, 200001, Colombia
进行中（不再招募）
Departamento de Córdoba
IMAT S.A.S ( Site 0504), Montería, Departamento de Córdoba, 230002, Colombia
进行中（不再招募）
Santander Department
Fundación Cardiovascular de Colombia ( Site 0503), Piedecuesta, Santander Department, 681017, Colombia
进行中（不再招募）
Valle del Cauca Department
Fundación Valle del Lili ( Site 0505), Cali, Valle del Cauca Department, 760032, Colombia
进行中（不再招募）
Clínica Imbanaco S.A.S ( Site 0509), Cali, Valle del Cauca Department, 760042, Colombia
进行中（不再招募）
Brno-mesto
Masarykuv onkologicky ustav-Klinika komplexni onkologicke pece ( Site 0553), Brno, Brno-mesto, 656 53, Czechia
Study Coordinator, 联系人, +420 543 136 216
招募中
Moravskoslezský kraj
Fakultni nemocnice Ostrava-Klinika onkologicka ( Site 0554), Ostrava, Moravskoslezský kraj, 708 52, Czechia
Study Coordinator, 联系人, +420597372264
招募中
Olomoucký kraj
Fakultni nemocnice Olomouc-Onkologicka klinika ( Site 0555), Olomouc, Olomoucký kraj, 779 00, Czechia
Study Coordinator, 联系人, +420 588 444 699
招募中
Praha 5
Fakultni nemocnice v Motole-Onkologicka klinika 2. LF UK a FN Motol ( Site 0551), Prague, Praha 5, 150 06, Czechia
进行中（不再招募）
Capital Region
Rigshospitalet ( Site 0576), Copenhagen, Capital Region, 2100, Denmark
Study Coordinator, 联系人, +45 35453545
招募中
Region Syddanmark
Odense Universitetshospital-Department of oncology ( Site 0579), Odense, Region Syddanmark, 5000, Denmark
进行中（不再招募）
Vejle Sygehus ( Site 0578), Vejle, Region Syddanmark, 7100, Denmark
Study Coordinator, 联系人, +45 79405000
招募中
Northern Savonia
Kuopion Yliopistollinen Sairaala ( Site 0603), Kuopio, Northern Savonia, 70210, Finland
Study Coordinator, 联系人, 35817173311
招募中
Pirkanmaa
Tampereen yliopistollinen sairaala ( Site 0604), Tampere, Pirkanmaa, 33520, Finland
Study Coordinator, 联系人, 358331166811
招募中
Southwest Finland
Turku University Hospital-Department of Oncology ( Site 0601), Turku, Southwest Finland, 20520, Finland
Study Coordinator, 联系人, 35823130729
招募中
Alsace
Institut de cancérologie Strasbourg Europe (ICANS) ( Site 0627), Strasbourg, Alsace, 67200, France
Study Coordinator, 联系人, +33368767207
招募中
Gard
Centre Hospitalier Universitaire de Nîmes - Institut de Cancérologie du Gard - Hôpital Universitaire ( Site 0630), Nîmes, Gard, 30029, France
进行中（不再招募）
Ille-et-Vilaine
Centre Eugène Marquis Rennes - Centre de Lutte Contre le Cancer ( Site 0632), Rennes, Ille-et-Vilaine, 35042, France
Study Coordinator, 联系人, 1-888-577-8839
招募中
Puy-de-Dome
Centre Jean Perrin - Centre Régional de Lutte contre le Cancer d'Auvergne ( Site 0629), Clermont-Ferrand, Puy-de-Dome, 63003, France
Study Coordinator, 联系人, +33473278005
招募中
Pyrenees-Atlantiques
Centre Hospitalier de la Côte Basque ( Site 0633), Bayonne, Pyrenees-Atlantiques, 64109, France
Study Coordinator, 联系人, 33559443535
招募中
Val-de-Marne
Gustave Roussy ( Site 0626), Villejuif, Val-de-Marne, 94800, France
Study Coordinator, 联系人, 1-888-577-8839
招募中
Hôpital Européen Georges Pompidou ( Site 0628), Paris, 75015, France
Study Coordinator, 联系人, 1-888-577-8839
招募中
Bavaria
klinikum rechts der isar der technischen universität münchen-Urologische Klinik und Poliklinik ( Site 0696), Munich, Bavaria, 81675, Germany
进行中（不再招募）
Mecklenburg-Vorpommern
HELIOS Kliniken Schwerin ( Site 0694), Schwerin, Mecklenburg-Vorpommern, 19055, Germany
Study Coordinator, 联系人, +493855202120
招募中
North Rhine-Westphalia
Universitätsklinikum Bonn-Klinik und Poliklinik für Urologie und Kinderurologie ( Site 0680), Bonn, North Rhine-Westphalia, 53127, Germany
Study Coordinator, 联系人, +4922828714249
招募中
Universitätsklinikum Münster - Albert Schweitzer Campus-Klinik für Urologie ( Site 0678), Münster, North Rhine-Westphalia, 48149, Germany
Study Coordinator, 联系人, 0049251-8344658
招募中
Schleswig-Holstein
Universitätsklinikum Schleswig-Holstein-Klinik für Urologie ( Site 0691), Lübeck, Schleswig-Holstein, 23538, Germany
Study Coordinator, 联系人, +4945150043699
招募中
Thuringia
Universitätsklinikum Jena-Klinik und Poliklinik für Urologie ( Site 0682), Jena, Thuringia, 07747, Germany
Study Coordinator, 联系人, +49 3641 9 32 9947
招募中
Charité Universitaetsmedizin Berlin - Campus Mitte ( Site 0679), Berlin, 10117, Germany
Study Coordinator, 联系人, 0049 30 450615297
招募中
Universitaetsklinikum Hamburg-Eppendorf-Onkologisches Zentrum ( Site 0705), Hamburg, 20246, Germany
Study Coordinator, 联系人, +4915222815585
招募中
Bács-Kiskun county
Bacs-Kiskun Varmegyei Oktatokorhaz-Onkoradiologiai Kozpont ( Site 0752), Kecskemét, Bács-Kiskun county, 6000, Hungary
Study Coordinator, 联系人, +3676516719
招募中
Nógrád megye
Nograd Varmegyei Szent Lazar Korhaz-Onkologia es Sugarterapias Osztaly ( Site 0761), Salgótarján, Nógrád megye, 3100, Hungary
Study Coordinator, 联系人, +3632522000
招募中
Pest County
Országos Onkológiai Intézet-Urogenitális Tumorok és Klinikai Farmakológiai Osztály ( Site 0756), Budapest, Pest County, 1122, Hungary
Study Coordinator, 联系人, +36122486001171
招募中
Debreceni Egyetem Klinikai Kozpont-Onkológiai Klinika ( Site 0758), Debrecen, 4032, Hungary
Study Coordinator, 联系人, +3652411717
招募中
Dublin
St. Vincent's University Hospital ( Site 0802), Dublin, Dublin, D04 T6F4, Ireland
Study Coordinator, 联系人, 1-888-577-8839
招募中
Tallaght University Hospital ( Site 0801), Dublin, D24 NR0A, Ireland
Study Coordinator, 联系人, 1-888-577-8839
招募中
Emek Medical Center ( Site 0830), Afula, 1834111, Israel
Study Coordinator, 联系人, 0546708579
招募中
Rambam Health Care Campus-Oncology Division ( Site 0826), Haifa, 3109601, Israel
Study Coordinator, 联系人, 04-7776234
招募中
Hadassah Medical Center ( Site 0833), Jerusalem, 9112001, Israel
Study Coordinator, 联系人, 02-6777111
招募中
Meir Medical Center. ( Site 0832), Kfar Saba, 4428164, Israel
Study Coordinator, 联系人, 1-888-577-8839
招募中
Rabin Medical Center ( Site 0828), Petah Tikva, 4941492, Israel
Study Coordinator, 联系人, 972-50-3745684
招募中
Sheba Medical Center ( Site 0827), Ramat Gan, 5265601, Israel
Study Coordinator, 联系人, : +972-35302191
招募中
Emilia-Romagna
IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori"-Oncologia Medica ( Site 0879), Meldola, Emilia-Romagna, 47014, Italy
Study Coordinator, 联系人, +390543739100
招募中
Lombardy
Fondazione IRCCS Istituto Nazionale dei Tumori-Struttura Complessa Oncologia Medica 1 ( Site 0877), Milan, Lombardy, 20133, Italy
Study Coordinator, 联系人, 00390223903033
招募中
Ospedale San Raffaele-Oncologia Medica ( Site 0876), Milan, 20132, Italy
Study Coordinator, 联系人, +390226435668
招募中
Chiba
Toho University Sakura Medical Center ( Site 0906), Sakura, Chiba, 285-8741, Japan
Study Coordinator, 联系人, +81434628811
招募中
Ehime
Ehime University Hospital ( Site 0918), Tōon, Ehime, 791-0295, Japan
Study Coordinator, 联系人, +81-89-964-5111
招募中
Fukuoka
Hospital of the University of Occupational and Environmental Health, Japan ( Site 0921), Kitakyushu, Fukuoka, 807-8556, Japan
进行中（不再招募）
Kurume University Hospital ( Site 0920), Kurume, Fukuoka, 830-0011, Japan
Study Coordinator, 联系人, +81-942-35-3311
招募中
Hokkaido
Asahikawa Medical University Hospital ( Site 0901), Asahikawa, Hokkaido, 078-8510, Japan
Study Coordinator, 联系人, +81-166-65-2111
招募中
Sapporo Medical University Hospital ( Site 0902), Sapporo, Hokkaido, 060-8543, Japan
Study Coordinator, 联系人, +81-11-611-2111
招募中
Hokkaido University Hospital ( Site 0931), Sapporo, Hokkaido, 060-8648, Japan
Study Coordinator, 联系人, +81117161161
招募中
Hyōgo
Kobe University Hospital ( Site 0914), Kobe, Hyōgo, 650-0017, Japan
Study Coordinator, 联系人, +81783825111
招募中
Ishikawa-ken
Kanazawa Medical University Hospital ( Site 0909), Mukai-awagasaki, Ishikawa-ken, 920-0265, Japan
Study Coordinator, 联系人, +81-76-286-3511
招募中
Kagawa-ken
Kagawa University Hospital ( Site 0917), Kita, Kagawa-ken, 761-0701, Japan
Study Coordinator, 联系人, +81878985111
招募中
Kanagawa
Yokohama City University Medical Center ( Site 0908), Yokohama, Kanagawa, 232-0024, Japan
Study Coordinator, 联系人, +81452615656
招募中
Nagasaki
National Hospital Organization Nagasaki Medical Center ( Site 0923), Ōmura, Nagasaki, 856-8562, Japan
Study Coordinator, 联系人, +81-957-52-3121
招募中
Nara
Nara Medical University Hospital ( Site 0915), Kashihara, Nara, 634-8522, Japan
进行中（不再招募）
Okinawa
Nanbu Tokushukai Hospital ( Site 0930), Shimajiri, Okinawa, 901-0417, Japan
Study Coordinator, 联系人, +81-98-998-3221
招募中
Osaka
Kansai Medical University Hospital ( Site 0912), Hirakata, Osaka, 573-1191, Japan
Study Coordinator, 联系人, +81-72-804-0101
招募中
Bell Land General Hospital ( Site 0913), Sakai, Osaka, 599-8247, Japan
Study Coordinator, 联系人, +81722342001
招募中
The University of Osaka Hospital ( Site 0911), Suita, Osaka, 565-0871, Japan
Study Coordinator, 联系人, +81668795111
招募中
Saga-ken
Saga-Ken Medical Centre Koseikan ( Site 0922), Saga, Saga-ken, 840-8571, Japan
进行中（不再招募）
Tokyo
The Jikei University Hospital ( Site 0907), Minato, Tokyo, 105-8471, Japan
进行中（不再招募）
Akita University Hospital ( Site 0904), Akita, 010-8543, Japan
Study Coordinator, 联系人, +81188341111
招募中
Kyushu University Hospital ( Site 0919), Fukuoka, 812-8582, Japan
Study Coordinator, 联系人, +81926411151
招募中
Fukushima Medical University Hospital ( Site 0933), Fukushima, 960-1295, Japan
Study Coordinator, 联系人, +81245471111
招募中
Gifu University Hospital ( Site 0910), Gifu, 501-1112, Japan
Study Coordinator, 联系人, +81-58-230-6000
招募中
Hiroshima University Hospital ( Site 0916), Hiroshima, 734-8551, Japan
Study Coordinator, 联系人, +81-82-257-5555
招募中
Kagoshima University Hospital ( Site 0929), Kagoshima, 890-8520, Japan
Study Coordinator, 联系人, +81-99-275-5111
招募中
National Hospital Organization Kumamoto Medical Center ( Site 0924), Kumamoto, 860-0008, Japan
Study Coordinator, 联系人, +81963536501
招募中
Miyazaki Prefectural Miyazaki Hospital ( Site 0927), Miyazaki, 880-8510, Japan
Study Coordinator, 联系人, +81985244181
招募中
University of Miyazaki Hospital ( Site 0926), Miyazaki, 889-1692, Japan
Study Coordinator, 联系人, +81-98-585-1510
招募中
Nagano Municipal Hospital ( Site 0932), Nagano, 381-8551, Japan
Study Coordinator, 联系人, +81-26-295-1199
招募中
National Hospital Organization Oita Medical Center ( Site 0925), Ōita, 870-0263, Japan
进行中（不再招募）
Jalisco
CIO - Centro de Inmuno-Oncología de Occidente ( Site 1103), Guadalajara, Jalisco, 44630, Mexico
进行中（不再招募）
Mexico City
Quemex Medical and Research ( Site 1112), Mexico City, Mexico City, 14308, Mexico
进行中（不再招募）
Nuevo León
Filios Alta Medicina ( Site 1106), Monterrey, Nuevo León, 64460, Mexico
进行中（不再招募）
Yucatán
Medical Care and Research SA de CV ( Site 1108), Mérida, Yucatán, 97070, Mexico
进行中（不再招募）
Centro de Investigacion Clinica de Oaxaca ( Site 1109), Oaxaca City, 68020, Mexico
进行中（不再招募）
Gelderland
Radboudumc-Medical Oncology ( Site 1152), Nijmegen, Gelderland, 6525 GA, Netherlands
Study Coordinator, 联系人, +31 (0)24 361 0353
招募中
Limburg
Zuyderland Medical Centre-Trialbureau Interne Geneeskunde ( Site 1163), Sittard-Geleen, Limburg, 6162 BG, Netherlands
进行中（不再招募）
VieCuri Medisch Centrum ( Site 1173), Venlo, Limburg, 5912 BL, Netherlands
进行中（不再招募）
North Brabant
ETZ Elisabeth-Internal Medicine ( Site 1160), Tilburg, North Brabant, 5022 GC, Netherlands
Study Coordinator, 联系人, +3113221 0210
招募中
North Holland
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 1153), Amsterdam, North Holland, 1066 CX, Netherlands
Study Coordinator, 联系人, +31205122569
招募中
Amsterdam UMC, locatie VUmc ( Site 1156), Amsterdam, North Holland, 1081 HV, Netherlands
进行中（不再招募）
Spaarne Gasthuis - Hoofddorp-Oncology ( Site 1170), Hoofddorp, North Holland, 2134 TM, Netherlands
Study Coordinator, 联系人, +31232245802
招募中
Provincie Friesland
Medische Centrum Leeuwarden ( Site 1172), Leeuwarden, Provincie Friesland, 8934 AD, Netherlands
Study Coordinator, 联系人, +31582866660
招募中
South Holland
Franciscus Gasthuis & Vlietland, Locatie Vlietland ( Site 1151), Schiedam, South Holland, 3118 JH, Netherlands
Study Coordinator, 联系人, 003110- 4617590
招募中
Haga Ziekenhuis locatie Leyweg-Oncology ( Site 1164), The Hague, South Holland, 2545 AA, Netherlands
Study Coordinator, 联系人, +31702102143
招募中
Utrecht
Meander Medisch Centrum ( Site 1157), Amersfoort, Utrecht, 3813TZ, Netherlands
Study Coordinator, 联系人, +003133 - 850 1189
招募中
Bay of Plenty
Tauranga Hospital-Bay of Plenty Clinical Trials Unit ( Site 1201), Tauranga, Bay of Plenty, 3112, New Zealand
Study Coordinator, 联系人, +64277033845
招募中
Otago
Dunedin Hospital-Southern Blood and Cancers Service ( Site 1203), Dunedin, Otago, 9016, New Zealand
Study Coordinator, 联系人, +64 3 470 9692
招募中
Akershus
Akershus Universitetssykehus-Onkologisk avdeling ( Site 1227), Lørenskog, Akershus, 1474, Norway
Study Coordinator, 联系人, +4767963800
招募中
Sor-Trondelag
St. Olavs Hospital-Kreftklinikken ( Site 1231), Trondheim, Sor-Trondelag, 7030, Norway
进行中（不再招募）
Østfold fylke
Sykehuset Østfold Kalnes ( Site 1228), Sarpsborg, Østfold fylke, 1714, Norway
进行中（不再招募）
Departamento de Junín
Instituto Regional de Enfermedades Neoplasicas del Centro (IREN CENTRO) ( Site 1258), Concepción, Departamento de Junín, 12125, Peru
Study Coordinator, 联系人, 1-888-577-8839
招募中
La Libertad
Clínica Sánchez Ferrer ( Site 1261), Trujillo, La Libertad, 13009, Peru
Study Coordinator, 联系人, 1-888-577-8839
招募中
Aliada-Oncologìa ( Site 1257), Lima, 15036, Peru
进行中（不再招募）
IPOR Instituto Peruano de Oncología & Radioterapia-Centro de Investigación ( Site 1254), Lima, 15036, Peru
进行中（不再招募）
Oncosalud-Clinical Research ( Site 1260), Lima, 15036, Peru
进行中（不再招募）
INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS-Medical Oncology ( Site 1256), Lima, 15038, Peru
Study Coordinator, 联系人, 1-888-577-8839
招募中
Kuyavian-Pomeranian Voivodeship
Centrum Onkologii im. Prof. Franciszka Lukaszczyka-Ambulatorium Chemioterapii ( Site 1302), Bydgoszcz, Kuyavian-Pomeranian Voivodeship, 85-796, Poland
Study Coordinator, 联系人, +48523743589
招募中
Regionalny Szpital Specjalistyczny im. dr. Władyslawa Biegańskiego ( Site 1316), Grudziądz, Kuyavian-Pomeranian Voivodeship, 86-300, Poland
Study Coordinator, 联系人, +48566414444
招募中
Wojewodzki Szpital Zespolony im Ludwika Rydygiera w Toruniu ( Site 1304), Torun, Kuyavian-Pomeranian Voivodeship, 87-100, Poland
进行中（不再招募）
Masovian Voivodeship
Mazowiecki Szpital Wojewódzki w Siedlcach-Siedleckie Centrum Onkologii ( Site 1310), Siedlce, Masovian Voivodeship, 08-110, Poland
Study Coordinator, 联系人, +48256403301
招募中
West Pomeranian Voivodeship
Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 1303), Koszalin, West Pomeranian Voivodeship, 75-581, Poland
Study Coordinator, 联系人, +48943488930
招募中
Zachodniopomorskie Centrum Onkologii ( Site 1311), Szczecin, West Pomeranian Voivodeship, 71-730, Poland
Study Coordinator, 联系人, +48914251502
招募中
Świętokrzyskie Voivodeship
Swietokrzyskie Centrum Onkologii, Samodzielny Publiczny Zakl-Klinika Onkologii Klinicznej, Dzial Ch ( Site 1318), Kielce, Świętokrzyskie Voivodeship, 25-734, Poland
Study Coordinator, 联系人, +48413674811
招募中
Puerto Rico Medical Research Center LLC ( Site 1354), Hato Rey, 00917, Puerto Rico
进行中（不再招募）
Ad-Vance Medical Research-Research ( Site 1353), Ponce, 00717, Puerto Rico
Study Coordinator, 联系人, 787-651-6697
招募中
Pan American Center for Oncology Trials - Ciudadela ( Site 1351), San Juan, 00909, Puerto Rico
进行中（不再招募）
Seoul
Asan Medical Center-Oncology ( Site 1402), Songpagu, Seoul, 05505, South Korea
进行中（不再招募）
Seoul National University Hospital-Oncology ( Site 1401), Seoul, 03080, South Korea
Study Coordinator, 联系人, +82220721672
招募中
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1404), Seoul, 03722, South Korea
Study Coordinator, 联系人, +82222288138
招募中
Samsung Medical Center ( Site 1405), Seoul, 06351, South Korea
Study Coordinator, 联系人, +82234101767
招募中
Cadiz
Hospital Jerez de la Frontera ( Site 1427), Jerez de la Frontera, Cadiz, 11407, Spain
Study Coordinator, 联系人, +34661753582
招募中
Madrid, Comunidad de
Hospital Universitario Ramón y Cajal-Medical Oncology ( Site 1431), Madrid, Madrid, Comunidad de, 28034, Spain
Study Coordinator, 联系人, 34913368263
招募中
Hospital Universitario 12 de Octubre-Medical Oncology ( Site 1433), Madrid, Madrid, Comunidad de, 28041, Spain
Study Coordinator, 联系人, 608464547
招募中
Orense
Complexo Hospitalario Universitario de Ourense ( Site 1426), Ourense, Orense, 32005, Spain
Study Coordinator, 联系人, +34988385471
招募中
Valenciana, Comunitat
Fundación Instituto Valenciano de Oncología-Oncologico ( Site 1430), Valencia, Valenciana, Comunitat, 46009, Spain
Study Coordinator, 联系人, +34 961114229
招募中
Hospital Lucus Augusti-Oncology ( Site 1432), Lugo, 27003, Spain
Study Coordinator, 联系人, +34982296459
招募中
HOSPITAL UNIVERSITARIO VIRGEN DEL ROCIO-Medical Oncology ( Site 1428), Seville, 41013, Spain
Study Coordinator, 联系人, 34955013068
招募中
Stockholm County
Karolinska Universitetssjukhuset Solna ( Site 1478), Stockholm, Stockholm County, 171 64, Sweden
进行中（不再招募）
Uppsala County
Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 1477), Uppsala, Uppsala County, 751 85, Sweden
Study Coordinator, 联系人, 0046186110000
招募中
Västra Götaland County
Sahlgrenska Universitetssjukhuset ( Site 1479), Gothenburg, Västra Götaland County, 413 45, Sweden
Study Coordinator, 联系人, 0046313421000
招募中
Bangkok
Chulalongkorn University ( Site 1530), Bangkok, Bangkok, 10330, Thailand
Study Coordinator, 联系人, 1-888-577-8839
招募中
Faculty of Medicine Siriraj Hospital ( Site 1531), Bangkok, Bangkok, 10700, Thailand
Study Coordinator, 联系人, 1-888-577-8839
招募中
Changwat Khon Kaen
Faculty of Medicine - Khon Kaen University ( Site 1526), Muang, Changwat Khon Kaen, 40002, Thailand
Study Coordinator, 联系人, +66 43 366568-9
招募中
Changwat Songkhla
Songklanagarind hospital ( Site 1527), Hat Yai, Changwat Songkhla, 90110, Thailand
Study Coordinator, 联系人, 1-888-577-8839
招募中
Baskent University Dr. Turgut Noyan Research and Training Center-ONCOLOGY ( Site 1554), Adana, 01250, Turkey (Türkiye)
Study Coordinator, 联系人, +903223444444
招募中
Gulhane Egitim Arastirma Hastanesi ( Site 1558), Ankara, 06010, Turkey (Türkiye)
Study Coordinator, 联系人, 1-888-577-8839
招募中
Hacettepe Universite Hastaneleri-oncology hospital ( Site 1551), Ankara, 06230, Turkey (Türkiye)
Study Coordinator, 联系人, 1-888-577-8839
招募中
Memorial Ankara Hastanesi-Medical Oncology ( Site 1557), Ankara, 06520, Turkey (Türkiye)
Study Coordinator, 联系人, 903122536666
招募中
Ankara Bilkent Şehir Hastanesi-Medical Oncology ( Site 1552), Ankara, 06800, Turkey (Türkiye)
Study Coordinator, 联系人, 1-888-577-8839
招募中
Istanbul Universitesi Cerrahpasa-Medical Oncology ( Site 1555), Istanbul, 34668, Turkey (Türkiye)
Study Coordinator, 联系人, 1-888-577-8839
招募中
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi-oncology ( Site 1553), Istanbul, 34722, Turkey (Türkiye)
Study Coordinator, 联系人, +902166065200
招募中
Samsun Medical Park Hastanesi-medical oncology (1560), Samsun, 55200, Turkey (Türkiye)
Dilek Erdem, 联系人, 905364247616, [email protected]
招募中
Cambridgeshire
Addenbrooke's Hospital ( Site 1605), Cambridge, Cambridgeshire, CB2 2QQ, United Kingdom
Study Coordinator, 联系人, 01223216083
招募中
England
The Royal Cornwall Hospital ( Site 1610), Truro, England, TR1 3LJ, United Kingdom
Study Coordinator, 联系人, 01872258345
招募中
Glasgow City
The Beatson West of Scotland Cancer Centre ( Site 1603), Glasgow, Glasgow City, G12 0YN, United Kingdom
Study Coordinator, 联系人, 1-888-577-8839
招募中
Hammersmith and Fulham
Charing Cross Hospital-Oncology Research ( Site 1606), London, Hammersmith and Fulham, W6 8RF, United Kingdom
Study Coordinator, 联系人, 0208 331 10277
招募中
London, City of
University College London Hospital ( Site 1612), London, London, City of, NW1 2PG, United Kingdom
进行中（不再招募）
The Christie NHS Foundation Trust ( Site 1608), Manchester, m20 4bx, United Kingdom
Study Coordinator, 联系人, +441614463000
招募中